Assessing the Concurrent Validity of the Australian Treatment Outcomes Profile in a Methamphetamine Dependent Treatment-Seeking Population.

Drug Alcohol RevSep 1, 2026
Clinical ResearchPsychiatryOpen access

Brendan Clifford, Rachel M Deacon, Kristie Mammen et al.

✦ AI-curated · Sources linked

In 30 seconds

This validation study assessed the Australian Treatment Outcomes Profile (ATOP) in a treatment-seeking population of 118 adults with methamphetamine dependence. Conducted as part of a randomized double-blind placebo-controlled trial, the study found strong concurrent validity for various health and substance use measures, indicating that ATOP is a reliable tool for this demographic.

Key findings

  • Strong validity was demonstrated for physical health, psychological health, and quality of life items.
  • Days of use for amphetamines, alcohol, cannabis, and cocaine showed strong validity.
  • Weak validity was found for days of benzodiazepine use.
  • Fewer than five participants endorsed heroin and other opioid use days, preventing assessment.

Why it matters

The validation of ATOP for methamphetamine-dependent individuals enhances the ability to monitor treatment outcomes effectively. Clinicians can utilize this tool to assess various aspects of health and substance use, improving care and treatment strategies.

Source

PubMed · PMID 42576154Free full text on PubMed Central

Published in Drug Alcohol Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.